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antibody-opsonised Plasmodium falciparum
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monocyte subsets, and require CD16 and
complement to do so
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Background: With more than 600,000 deaths from malaria, mainly of children under five years old and caused by
infection with Plasmodium falciparum, comes an urgent need for an effective anti-malaria vaccine. Limited details
on the mechanisms of protective immunity are a barrier to vaccine development. Antibodies play an important role
in immunity to malaria and monocytes are key effectors in antibody-mediated protection by phagocytosing
antibody-opsonised infected erythrocytes (IE). Eliciting antibodies that enhance phagocytosis of IE is therefore an
important potential component of an effective vaccine, requiring robust assays to determine the ability of elicited
antibodies to stimulate this in vivo. The mechanisms by which monocytes ingest IE and the nature of the monocytes
which do so are unknown.
Methods: Purified trophozoite-stage P. falciparum IE were stained with ethidium bromide, opsonised with anti-
erythrocyte antibodies and incubated with fresh whole blood. Phagocytosis of IE and TNF production by individual
monocyte subsets was measured by flow cytometry. Ingestion of IE was confirmed by imaging flow cytometry.
Results: CD14hiCD16+ monocytes phagocytosed antibody-opsonised IE and produced TNF more efficiently than
CD14hiCD16- and CD14loCD16+ monocytes. Blocking experiments showed that Fcγ receptor IIIa (CD16) but not Fcγ
receptor IIa (CD32a) or Fcγ receptor I (CD64) was necessary for phagocytosis. CD14hiCD16+ monocytes ingested
antibody-opsonised IE when peripheral blood mononuclear cells were reconstituted with autologous serum but not
heat-inactivated autologous serum. Antibody-opsonised IE were rapidly opsonised with complement component C3 in
serum (t1/2 = 2-3 minutes) and phagocytosis of antibody-opsonised IE was inhibited in a dose-dependent manner by an
inhibitor of C3 activation, compstatin. Compared to other monocyte subsets, CD14hiCD16+ monocytes expressed the
highest levels of complement receptor 4 (CD11c) and activated complement receptor 3 (CD11b) subunits.
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Conclusions: We show a special role for CD14hiCD16+ monocytes in phagocytosing opsonised P. falciparum IE and
production of TNF. While ingestion was mediated by Fcγ receptor IIIa, this receptor was not sufficient to allow
phagocytosis; despite opsonisation with antibody, phagocytosis of IE also required complement opsonisation. Assays
which measure the ability of vaccines to elicit a protective antibody response to P. falciparum should consider their ability
to promote phagocytosis and fix complement.
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It is estimated that there are currently more than 200
million malaria infections per year, resulting in more
than 600,000 deaths, mainly of children under five years
old and caused by infection with Plasmodium falcip-
arum [1]. In addition, infection with P. falciparum dur-
ing pregnancy causes maternal malaria which results in
increased incidence of pre-term births, low infant birth
weight and maternal anaemia causing significant mor-
bidity and mortality [2, 3].
Antibody-mediated effector mechanisms against the
blood stages of the parasite’s life cycle are important
in protection against clinical malaria disease: in
malaria-endemic regions, acquisition of antibodies to
blood-stage parasites is associated with protection
against death due to severe malaria by five years of
age and with protection against clinical malaria by
early adulthood [4]. Important targets of protective
antibodies are antigens expressed on the surface of
infected erythrocytes (IE) [5], and the major target of
these antibodies is a surface protein known as
PfEMP1 [6]. In addition, acquisition of antibodies to
antigens exposed on the surface of IE that adhere
and accumulate in the placenta, and express the
PfEMP1 variant known as Var2CSA, occurs in a
gravidity-dependent manner and is associated with pro-
tection against maternal malaria as well as negative out-
comes such as anaemia and low birth weight [7–11].
The effector cells most likely to mediate protective
effects of antibodies against circulating blood stage
parasites are monocytes, which phagocytose IE [12].
They can also accumulate as malaria pigment-laden
cells in the placentas of malaria-infected pregnant
women [13–15]. Monocytes phagocytose IgG-opsonised
IE via Fcγ receptor-mediated mechanisms [16, 17] and
secrete both pro-inflammatory and anti-inflammatory
cytokines and growth factors in response to parasite
ingestion which may aid in both parasite clearance
and in limiting inflammation [18, 19]. Circulating hu-
man monocytes exist as separate subsets which are
identified by their expression of CD14 (the co-receptor
for Toll-like receptor 4 (TLR4) recognition of bacterial
lipopolysaccharide) and CD16 (FcγRIIIa: a receptor forIgG). The current convention is to define three subsets
of human monocytes: classical (CD14hiCD16-), non-
classical (CD14loCD16+) and intermediate (CD14hiCD16+)
monocytes [20]. The biological properties of these subsets
are governed by differing expression of pattern recogni-
tion and chemokine receptors. CD14hiCD16- classical
monocytes represent the major population in blood,
respond strongly to bacterial products via TLR4 and
infiltrate into sites of inflammation in response to
the chemokine CCL2 [21]. CD14loCD16+ non-classical
monocytes may patrol blood vessel walls and respond to
viral ligands via TLR7/8. They express high levels of frac-
talkine receptor (CX3CR1) but migrate in response to
multiple chemokines [21]. CD14hiCD16+ intermediate
monocytes may represent a transitional form of the mat-
uration of classical monocytes into non-classical mono-
cytes and respond strongly to both viral and bacterial
ligands [22]. The role of different monocyte subsets in
settings of parasite infection is not known.
While it is recognised that a successful vaccine strat-
egy must generate a robust antibody response to blood
stage parasites, the desired functional activities required
for protective immunity are less clear. Evidence is accu-
mulating that the ability of antibodies to promote
opsonic phagocytosis of blood stage parasites is an im-
portant component of immunity [23–26]. However, the
major cell subsets mediating phagocytosis and the
underlying mechanisms are poorly understood. This
knowledge may be crucial for the development of highly
protective vaccines. Monocyte phagocytosis of blood-
stage malaria parasites has been previously studied using
peripheral blood mononuclear cells or purified mono-
cytes which miss interactions between serum compo-
nents, uninfected erythrocytes and the phagocyte, and
have not usually considered individual monocyte subset
responses. Here we use a whole blood phagocytosis assay
[27] to show for the first time that CD14hiCD16+ inter-
mediate monocytes have a much greater phagocytic ac-
tivity towards trophozoite stage malaria parasites than
other monocyte subsets. Our results uncover an essen-
tial role for Fcγ receptor IIIa (CD16a) and show that
complement opsonisation is required for IgG-mediated
phagocytic uptake under physiological conditions and




Blood was obtained by venepuncture with informed
consent from healthy volunteers without a history of
malaria infection using protocols approved by The Alfred
Hospital Research and Ethics Unit. Five serum samples
with high IgG reactivity to CS2 IE were pooled from sam-
ples collected from pregnant women in an endemic region
of Papua New Guinea [28]. All women gave informed
written consent and ethics approval was provided by the
Medical Research Advisory Committee, PNG).
Parasite culture and purification
P. falciparum laboratory lines CS2 [29] and E8B [30]
were grown in human erythrocytes (group O, Rh+,
Australian Red Cross Blood Service) at 37 °C with 5 %
CO2 suspended in RPMI-HEPES medium supple-
mented with 50 μg/ml hypoxanthine, 25 nM NaHCO3,
20 μg/ml gentamicin, 5 % heat inactivated pooled hu-
man serum and 5 % Albumax. Gelatin enrichment of
knob-expressing IE was performed weekly, and IE
were synchronised weekly by resuspension of culture
pellets in 5 % sorbitol in water to lyse trophozoite and
schizont IE. Mature pigmented trophozoite stage IE
were enriched by centrifugation over Percoll gradients
to >80 % purity as assessed by counting Giemsa-stained
thin blood smears by microscopy.
Infected erythrocyte labeling and opsonisation
IE were opsonised at a concentration of 5 x 107 tropho-
zoites/mL for 30 minutes at room temperature with
rabbit anti-human erythrocyte antibodies (Cappel, MP
Biomedicals, LLC; Santa Anna, CA, USA) using a sub-
agglutinating 1/800 dilution of antibody in phosphate-
buffered saline (PBS). In some experiments CS2 IE were
opsonised with 20 % human immune serum from a pool
of sera prepared from pregnant woman with placental
malaria enrolled in the VT cohort in Papua New Guinea
[31]. Opsonised cells were washed in fluorescence-
activated cell sorting (FACS) wash buffer (PBS, 2 % new
born calf serum) and resuspended in PBS (2 x 108/mL)
then stained with 10 μg/mL ethidium bromide (EtBr) for
30 minutes at room temperature. Following labeling
with EtBr, cells were washed three times with cold FACS
wash buffer and used immediately.
Whole blood phagocytosis assay
A sample of 5 mL whole blood was collected from
healthy volunteers into lithium heparin blood collection
tubes by venepuncture and analysed within two hours of
collection. Aliquots of 50 μL whole blood were placed inpolypropylene FACS tubes, then 1 x 107 EtBr-labeled IE
were added. This is a ratio of approximately 200 IE per
peripheral blood mononuclear cell. Cells were incubated
for 30 minutes at 37 °C, or on ice as a control. After
phagocytosis, cells were lysed with 3 mL 0.2 % ammo-
nium chloride for five minutes at 22 °C, then washed
with 3 mL cold FACS wash buffer. Supernatant was re-
moved and cells were resuspended in 100 μL PBS. Cells
were stained with antibodies for 30 minutes on ice,
washed, then fixed with 2 % formaldehyde and analysed
immediately by flow cytometry using a FACS Canto II
flow cytometer (BD Biosciences, San Jose, CA, USA).
Monocyte subsets were identified by staining with anti
CD14 APC (M5E2, BD Biosciences) and CD16 FITC
(3G8, BD Biosciences), and phagocytosis was determined
by measuring EtBr fluorescence in the PE channel. Gates
were set using samples incubated with unopsonised,
EtBr-stained IE at 37 °C. Flow data were analysed using
FlowJo (version 8, Tree Star Inc.). For blocking experi-
ments, blood was pre-incubated with the indicated con-
centrations of blocking antibodies for 30 minutes at 4 °C
before the addition of IgG-opsonised IE. The antibodies
used were 3G8 (in house (MH): blocking antibody for
CD16), Fab fragment of IV.3 (in house (MH): blocking
Ab for CD32a), 10.1 (Santa Cruz Biotechnology, Dallas,
TX, USA : blocking Ab for CD64), H1-111 (Biolegend,
San Diego, CA, USA: blocking antibody for CD11a),
Bear-1 (Abcam, Cambridge, UK: blocking antibody for
CD11b) and clone 3.9 (Biolegend: blocking antibody for
CD11c). The antibody used to measure C3b deposition
of RBC was FITC-conjugated goat fraction to human
complement C3, (MP Biomedical 0855167). To measure
the effect of inhibiting complement activation on phago-
cytosis, compstatin (R&D Systems, Minneapolis, MN,
USA) was added to whole blood, from stock solutions
(2 mg/ml) prepared in PBS, to a final concentration of
0–50 μM, and incubated for 15 minutes on ice before
addition of iRBC and transfer to 37 °C to measure
phagocytosis.
Monocyte phenotyping
Aliquots of peripheral blood mononuclear cells (PBMC)
from malaria-naive healthy individuals recruited in
Melbourne were incubated with predetermined saturat-
ing concentrations of the relevant antibodies. Monocytes
were gated using forward and side scatter and mono-
cyte subsets identified with CD16 PE Cy7 (3G8, BD
Biosciences) and CD14 BV510 (M5E2, Biolegend) or
APC (M5E2, BD Biosciences). antibodies used were:
CD16 PE Cy7 (3G8, BD Biosciences), CD32a (IV.3 bi-
otinylated Fab fragment + streptavidin APC), CD32b (in
house (MH), 63X-21 biotinylated whole IgG + streptavidin
APC) [32], CD64 PerCP 5.5 (10.1, Biolegend), CD11a
Alexa-488 (HI111, Biolegend), CD11b APC (ICRF44,
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CD11c V450 (B-ly6, BD Biosciences), CD35 FITC (E11,
Biolegend).
Intracellular TNF measurements
Phagocytosis of infected red blood cells (iRBC) was per-
formed using 100 μL aliquots of whole blood as de-
scribed above except that iRBC were not labeled with
EtBr. A total of 20 μg/mL brefeldin A and 10 μM mon-
ensin was added and the cells incubated for four hours
at 37 °C, stained with CD14 APC and CD16 PE Cy7
(30 minutes on ice), then permeabilised (Perm/Wash
Buffer 1, BD Biosciences). After 10 minutes on ice, cells
were stained with αTNF phycoerythrin (PE) (Mab11, BD
Biosciences) for 30 minutes, washed and fixed.
Imaging flow cytometry
IE were stained with PKH26 (Sigma-Aldrich, Castle Hill,
NSW, Australia) according to the manufacturer’s instruc-
tions. Aliquots of whole blood (50 μL) were incubated
with 5 x 106 PKH26-stained CS2-IE for 15 minutes, and
processed as above for whole blood phagocytosis except
that cells were stained with CD14 Pacific Blue (M5E2,
Biolegend) and CD16 PE Cy5 (3G8, BD Biosciences).
Samples were acquired using an ImageStream 100
imaging flow cytometer and analysed using IDEAS
software.
Results
CD14hiCD16+ monocytes in whole blood phagocytose IE
more efficiently than other monocyte subsets
Whole blood obtained from an individual with no previ-
ous history of malaria infection was incubated with
EtBr-stained CS2-IE, opsonised or not opsonised with
rabbit anti human RBC IgG, and phagocytosis analysed
by flow cytometry. The CS2 parasite isolate was chosen
both for its relevance to pregnancy-associated malaria
and because the lack of CD36 binding potentially
minimises the level of non-opsonic phagocytosis.
Events within the broad monocyte gate defined by for-
ward and side scatter were analysed on a CD14 versus
CD16 dot plot to define the three monocyte subsets
CD14hiCD16- “classical”, CD14hiCD16+ “intermediate”
and CD14loCD16+ “non-classical” monocytes (Fig. 1a).
The extent of IE phagocytosis by each monocyte subset
was determined from the intensity of EtBr fluorescence
and compared to the 4 °C negative control. There was
little or no phagocytosis of unopsonised IE by any
monocyte subset (Fig. 1a, right, upper panels). Opson-
isation with IgG increased phagocytosis of IE, particu-
larly by intermediate monocytes (Fig. 1a, right lower
panels). Surprisingly, we detected little IE ingestion
in the CD14hiCD16- or the CD14loCD16+ subsets.
CD14hiCD16+ monocytes showed much higherphagocytosis of both IgG-opsonised and non-
opsonised IE with the CD14loCD16+ monocyte sub-
set showing the least amount of activity (Fig. 1b).
These differences were not due to generally higher
phagocytic activity of CD14hiCD16+ compared to other
monocyte subsets since when unopsonised Escherichia
coli was used as a target the classical subset showed the
highest degree of phagocytosis (Additional file 1: Figure
S1). Nor was it due to a greater ability of CD14hiCD16+
monocytes to phagocytose particles of the size of erythro-
cytes (7 μm diameter) since when IE were incubated with
isolated PBMC instead of whole blood the classical
monocyte subset ingested IgG-opsonised IE to a similar
extent (Fig. 1c). Since we used rabbit anti-human
erythrocyte IgG to opsonise IE to high levels, we next
confirmed that CD14hiCD16+ monocytes showed en-
hanced phagocytosis of IE opsonised with human IgG. IE
were opsonised with a pool of immune sera from women
with placental malaria who had a high titre of antibodies
recognising the CS2 isolate; CD14hiCD16+ monocytes
were again the only subset to substantially phagocyt-
ose parasites (Fig. 1d). CS2 is a P. falciparum line
that expresses Var2CSA. To determine if the in-
creased phagocytic capacity of CD14hiCD16+ mono-
cytes was specific to this parasite strain, we
incubated whole blood with E8B-IE. E8B is a malaria
strain that expresses a mixture of var genes that, in con-
trast to CS2, promote binding to CD36 and ICAM-1 [33,
34]. CD14hiCD16+ monocytes were the only monocyte
subset to efficiently ingest IgG-opsonised E8B-IE
(Fig. 1e) indicating that the specificity for
CD14hiCD16+ monocytes is independent of the
PfEMP-1 type. More monocytes ingested IE when
PBMC preparations were used in the phagocytosis
assay compared to whole blood (Fig. 1c c.f 1d). This was
true for both CD14hiCD16+ monocytes (median phago-
cytosis = 34.4 c.f. 10.4, p = 0.02) and for
CD14hiCD16- monocytes (median phagocytosis = 47.9 c.f.
4.22, p = 0.0007).
The higher phagocytic ability of CD14hiCD16+ monocytes,
that is evident in whole blood but not PBMC, is not due
to lower inhibition by RBC or plasma
Serum and uninfected RBC have been reported to
inhibit phagocytosis of iRBC [35]. To test whether unin-
fected RBC inhibit phagocytosis of IE, and whether this
inhibition is less for CD14hiCD16+ monocytes, we incu-
bated PBMC with titrated amounts of group O-negative
RBC then performed phagocytosis. RBC inhibited
phagocytosis by monocytes from all three subsets
present in PBMC when added at 25-200x the number of
PBMC (Additional file 2: Figure S2A). The maximum
ratio of RBC to PBMC used in this experiment was
200:1. This equates to a concentration of 1 x 109/ml
Fig. 1 (See legend on next page.)
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Fig. 1 CD14hiCD16+ intermediate monocytes phagocytose IE more efficiently than other monocytes. a Whole blood was incubated with EtBr-labelled
CS2-IE for 30 minutes then uningested RBC removed by hypotonic lysis and washing. Cells were stained with anti-CD14 and CD16, monocytes gated
using forward and side scatter then subsets defined as classical (C: CD14hiCD16-), intermediate (IM: CD14hiCD16+) and non-classical (NC: CD14loCD16+)
as shown. Histograms show EtBr staining of the three subsets incubated at 37 °C (red histograms) or 4 °C (blue histograms) with unopsonised (IE, top)
or opsonised (IgG-IE, bottom) IE. b Phagocytosis using blood from eight separate donors. Whole blood was incubated as in a with unopsonised CS2-IE
(left hand panels; IE) or CS2-IE opsonised with rabbit anti-human RBC antibody (right hand panels; IgG-IE) as indicated. c Phagocytosis by
monocyte subsets of IE opsonised with rabbit anti human RBC was measured using PBMC prepared from four separate donors (left hand
panels). Phagocytosis of IE opsonised with pooled human immune serum was measured using PBMC prepared from six separate donors
(right hand panels). d Phagocytosis of unopsonised CS2-IE (left hand panels; IE) and CS2-IE opsonised with pooled human immune serum
(right hand panels; IgG-IE) was measured in a whole blood assay as in a using blood from nine separate donors. e Phagocytosis using blood
from six separate donors. Whole blood was incubated as in a with unopsonised E8B-IE (left hand panels; IE) or E8B-IE opsonised with rabbit
anti-human RBC antibody (right hand panels; IgG-IE) as indicated. Background phagocytosis measured at 4 °C was subtracted from all data
points. The percent phagocytosis by intermediate (IM) monocytes was compared using pairwise comparisons in each case (b-e) with either
that by classical (C) monocytes or non-classical (NC) monocytes, as indicated. Differences between groups were assessed using Wilcoxon
matched pairs signed rank test: * p < .05, ** p <0.01. EtBr ethidium bromide, IE infected erythrocytes, PBMC peripheral blood monocytes;
RBC red blood cells
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blood (4-6 x 109/ml). To test whether components
present in human plasma inhibit monocyte phagocyt-
osis, PBMC were incubated with varying concentra-
tions of autologous heat-inactivated plasma then
phagocytosis measured as above. Plasma inhibited
phagocytosis of IgG-opsonised IE by all three mono-
cyte subsets and, in particular, of CD14hiCD16+ and
CD14hiCD16- monocytes equally (Additional file 2:
Figure S2B). Thus, uninfected RBC and human
plasma both inhibit phagocytosis of iRBC but their
presence does not account for the higher phagocyt-
osis by CD14hiCD16+ monocytes observed in whole
blood.Ingestion of IE by CD14hiCD16+ monocytes was
confirmed using imaging flow cytometry
We next incubated whole blood with opsonised IE for
15 minutes, lysed the uningested erythrocytes, then
analysed single cells in focus using imaging flow cy-
tometry (Additional file 3: Figure S3). A shorter time
was used to allow ingestion without substantial diges-
tion of the IE. Bright field images of intermediate
monocytes confirmed the presence of ingested para-
sites and the co-localisation of CD16 around the
phagosome. Manual counting of ingested parasites
using approximately 300 randomly selected bright field
images within their respective gates confirmed the
higher phagocytic index (PI) of CD14hiCD16+ mono-
cytes (33 parasites ingested per 324 monocytes ana-
lysed or PI = 10.2 parasites ingested per 100
monocytes) compared to CD14hiCD16- monocytes
(13/288 or PI = 4.51). The lower extent of phagocytosisin this experiment compared to the experiments
depicted in Fig. 1b is due to a lower concentration of
IE and the shorter time used.Complement opsonisation is absolutely required for
phagocytosis of IgG-opsonised IE in whole blood
Since the higher phagocytic activity by intermediate
monocytes was observed only when IE were added to
whole blood, but not to PBMC preparations, we rea-
soned that opsonins apart from IgG, such as comple-
ment components, might contribute to this activity.
We, therefore, centrifuged heparinised whole blood,
washed and reconstituted the cells to the original
blood volume using either autologous serum or heat-
inactivated autologous serum (collected in a separate
serum tube at the same time as blood collection), then
measured phagocytosis of CS2 IE. Phagocytosis was
not affected by washing and reconstituting the blood
cells in normal serum, but was abolished when heat-
inactivated serum was used (Fig. 2a). These data sug-
gest that complement opsonisation occurs during the
30 minute incubation of IE with whole blood and that
this opsonisation is essential for efficient phagocytosis
of IgG-opsonised IE by CD14hiCD16+ monocytes. To
verify this, we added purified, IgG-opsonised CS2-IE to
heparinised plasma for various times at 37 °C and mea-
sured deposition of C3b onto the opsonised IE by flow
cytometry. There was minimal C3b bound to IE at 0
time (Fig. 2b, left and middle panels; dark grey histo-
grams), or after 30 minutes in the absence of IgG op-
sonisation (Fig. 2b, left panel: light grey histogram),
but considerable deposition onto IgG-opsonised IE
after 30 minutes (Fig. 2b, middle panel: light grey
histogram). C3b was deposited onto IE with a half time
Fig. 2 Complement opsonisation is required for monocyte phagocytosis of antibody-opsonised IE a Monocyte phagocytosis of CS2-IE (Unop) or
CS2-IE opsonised with rabbit anti-human RBC antibody (OP) was determined using whole blood, whole blood reconstituted to its original
volume with autologous heat-inactivated plasma (HI plasma) or with autologous plasma (plasma) as indicated. Phagocytosis by classical
CD14hiCD16- (left hand panel), intermediate CD14hiCD16+ (middle panel) and non-classical CD14loCD16+ (right hand panel) monocytes were
measured. Data represent mean (sem) of independent experiments using blood from three separate donors. Differences between conditions were
assessed by one-way ANOVA using Tukey’s test for multiple comparisons. b Unopsonised CS2-IE or CS2-IE opsonised with rabbit anti-human RBC
antibody were added to heparinised plasma for 0 and 30 minutes at 37 °C, stained with antiC3, and RBC analysed by flow cytometry. His-
tograms represent C3 staining at 0 time (dark grey histogram) or 30 minutes (light grey histogram). Right hand panel represents C3 stain-
ing of CS2-IE opsonised with rabbit anti-human RBC antibody after incubation in heparinised plasma for the indicated times at 4 °C (solid
black circles) or 37 °C (open circles). c Compstatin (R&D Systems) was added to whole blood from stock solutions dissolved in PBS at the
indicated final concentrations then phagocytosis of CS2-IE opsonised with rabbit anti-human RBC antibody by intermediate (open circles)
or classical monocytes (solid black circles) determined (left hand panel) or non-classical monocytes (open squares) determined (right hand
panel). The absolute values of phagocytosis by non-classical monocytes were very low and hence these data are plotted separately. Data represent
mean (sem) of independent experiments using blood from three separate donors. ANOVA analysis of variance, IE infected erythrocytes, RBC red
blood cells, sem standard error of the mean
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plement deposition required IgG opsonisation suggests
that complement is fixed under these conditionsprimarily by the classical pathway. To determine the
significance of complement to IE phagocytosis by
monocytes in whole blood, we next examined the
Fig. 3 CD14hiCD16+ monocytes produce more TNF compared to other monocytes in response to IE. a Representative histograms showing
intracellular TNF staining of monocytes four hours after addition of CS2-IE (IE, left hand panels) or CS2-IE opsonised with rabbit anti-human RBC
antibody (IgG-IE, right hand panels). Grey histograms: 4 °C controls, red histograms: 37 °C. b Median (IQR) of intracellular TNF expression in classical
(C; solid black circles), intermediate (IM; open circles) and non-classical (NC; open squares) monocytes from four independent experiments using
blood from separate donors. IE infected erythrocytes, IQR interquartile range
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Compstatin inhibited phagocytosis of IgG-opsonised
IE by both CD14hiCD16- and CD14hiCD16+ mono-
cytes (Fig. 2c) showing that even when opsonised with
IgG, complement opsonisation is required for efficient
phagocytosis of IE. In these experiments phagocytosis
by CD14loCD16+ monocytes was very low and was
thus excluded from this analysis.
CD14hiCD16+ monocytes produced TNF in response to
IgG-opsonised IE
CD14hiCD16+ monocytes respond to phagocytosis of
bacterial pathogens by producing pro-inflammatory cy-
tokines such as TNF [22]. Since this is thought to be re-
quired for both effective immunity to malaria and for
immunopathogenesis we determined whether intermedi-
ate monocytes produce TNF in response to IE. Whole
blood was incubated with unopsonised and opsonised
CS2-IE for four hours, then intracellular TNF measured
by flow cytometry for all three subsets. There was no
TNF production in response to unopsonised IE (Fig. 3a,
left hand panels). Both CD14hiCD16- and CD14hiCD16+
monocytes produced TNF following addition of opso-
nised parasites, with more of the CD14hiCD16+ subset
producing TNF in agreement with their greater phago-
cytic potential, although this difference did not reach sig-
nificance, whereas CD14loCD16+ monocytes produced
very little (Fig. 3a, right hand panels and Fig. 3b).
Fcγ and complement receptors required for phagocytosis
of IE in whole blood
We next phenotyped monocytes from nine independent
donors to determine how the subsets differ with respect
to expression of receptors involved in binding and
phagocytosis of complement and IgG-opsonised targets.
Of the phagocytic Fcγ receptors, CD14hiCD16+ mono-
cytes expressed significantly higher levels of Fcγ receptor
IIa, CD32a, compared to the other subsets (Fig. 4a). The
level of the inhibitory Fcγ receptor, CD32b, was also
highest in this subset, although this receptor appeared to
be expressed at much lower levels than CD32a. With
respect to the phagocytic complement receptors, the
CD14hiCD16+ monocytes expressed the highest levels
of the α chain of CR4, CD11c. Of interest, however,
was the observation that although CD14hiCD16+
monocytes expressed levels of CD11b (the α chain of
CR3) that were intermediate between expression on
the CD14hiCD16- and CD14loCD16+ subsets, they
expressed the highest levels of activated CD11b suggest-
ing that inside-out signaling required for CR3 activation
was relatively stronger in this subset. CD14hiCD16+
monocytes also expressed the highest levels of the α
chain (CD11a) of the adhesion molecule LFA-1. Since
CD32a is the only Fcγ receptor expressed most highly onCD14hiCD16+ monocytes relative to other subsets we
reasoned that it may have a unique role in phagocytosis
of IgG-opsonised IE. We, therefore, used blocking
antibodies to determine which Fcγ receptors are required
for phagocytosis. Aliquots of whole blood were pre-
incubated for 30 minutes with blocking antibodies spe-
cific for CD16, CD32a and CD64, then IgG-opsonised
CS2 IE were added and phagocytosis measured after
30 minutes. The blocking antibody specific for CD16,
3G8, inhibited phagocytosis by CD14hiCD16+ and
CD14loCD16+ monocytes by approximately 90 % at
10–20 μg/mL (Fig. 4b upper panel) but, as expected,
had no effect on phagocytosis by CD14hiCD16-
monocytes which do not express CD16. This inhibition
was confirmed using whole blood from three individual
donors incubated with 10 μg/mL blocking antibodies
(Fig. 4b lower panel). In contrast, blocking antibodies
specific for CD32a, IV.3, and for CD64, 10.1, had no ef-
fect on phagocytosis by any subset despite these recep-
tors being expressed on all three subsets. Thus, CD16,
but not CD32a or CD64 is necessary for phagocytosis of
IgG-opsonised IE in whole blood. However, the fact that
non-classical monocytes express CD16 but phagocytose
IE poorly shows that CD16 expression is not sufficient.
Since complement opsonisation was also necessary for
phagocytosis of IgG-opsonised IE in whole blood, we in-
vestigated the effect of blocking antibodies to the phago-
cytic complement receptors CR1, CR3 and CR4 as well
as antibodies to LFA-1. Antibodies to the α chain of CR3
(CD11b) and CR4 (CD11c) showed minimal inhibition at
10 μg/mL but blocked more efficiently at higher concen-
trations (Fig. 4c). Anti CD11a did not inhibit phagocyt-
osis by any monocyte subset.
Discussion
Using a whole blood phagocytosis assay we studied the
properties of phagocytes under conditions resembling
those in vivo as closely as possible. We show that al-
though the CD14hiCD16- classical and CD14hiCD16+
intermediate monocyte subsets efficiently phagocytose
IE in PBMC preparations, only the CD14hiCD16+ subset
does so in whole blood. While the CD14hiCD16+ subset
is more efficient at phagocytosis on a per cell basis, the
greater number of CD14hiCD16- monocytes suggests
that they may also phagocytose significant numbers of
IE in vivo. We show for the first time that phagocytosis
of IgG-opsonised IE required complement opsonisation
and was strongly inhibited by inhibitors of complement
activation. Antibody blocking experiments showed that
in whole blood phagocytosis required expression of the
Fcγ receptor CD16, but not CD32a or CD64. Thus,
CD16 is necessary but not sufficient for phagocytosis
since non-classical monocytes, which also express CD16,
failed to phagocytose IE efficiently. This is likely due to
Fig. 4 (See legend on next page.)
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Fig. 4 Expression of Fcγ and complement receptors on monocyte subsets and the effect of blocking antibodies on phagocytosis by individual
subsets. a Expression of Fcγ and complement receptors on monocytes was determined by whole blood staining. Black bars: C, white bars: IM,
grey bars: NC. Bars represent mean (sem) of MFI using blood from nine separate donors (eight for CD32b). aCD11b refers to activated CD11b
defined by the epitope recognised by the CBRM 1/5 monoclonal antibody. Differences between subsets were assessed using Wilcoxon’s matched
pairs signed rank test. * p <0.05, ** p <0.01. b Whole blood was incubated for 30 minutes at 4 °C with the indicated concentrations of each
blocking antibody before addition of CS2-IE and determination of phagocytosis. Representative dose response curves from four independent
experiments, of inhibition of phagocytosis by closed black circles), IM monocytes (open circles) and NC monocytes (open squares) are shown
in the upper panels and data (mean, sem) from experiments with whole blood from three separate donors conducted using 10 μg/mL of each
blocking antibody are shown in the lower panels. c Effect of blocking LFA-1 (CD11a), CR3 (CD11b) and CR4 (CD11c) on phagocytosis of IgG
opsonised CS2-IE. Upper panels show dose response of the indicated blocking antibodies and lower panels show aggregate data (mean, sem
from n =3 independent experiments). Symbols are the same as in a and b. C classical, IM intermediate, N non-classical
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of activated CR3. Complement opsonisation of IE oc-
curred rapidly in situ during the assay, primarily via the
classical pathway as we did not detect complement de-
position on IE in the absence of IgG opsonisation. In
whole blood of children with malaria infection, IE have
C3b and C4 deposited on their surface [36] but it is not
clear whether the limiting factor for efficient phagocyt-
osis is the extent of complement fixation, opsonisation
with IgG or both. Our findings show that evaluation of
immunity in vaccine trials must also take into account
the ability of the elicited antibodies to fix complement as
well as to promote phagocytosis. The use of the CS2
strain in this study gives relevance to anti Var2CSA vac-
cines currently under development for pregnancy-
associated malaria and currently funded through to
clinical trials. It is essential to understand how anti-
bodies to Var2CSA function in order to design a vaccine
with maximum efficacy and to evaluate responses in
such trials.
We propose that co-operation between CD16 and
complement receptors are required in whole blood for
phagocytosis of IgG opsonised IE. Multiple complement
receptors are probably involved although a likely partner
for CD16 is CR3 (CD11b/CD18) which was more acti-
vated on intermediate monocytes than on other mono-
cyte subsets, and partial inhibition of phagocytosis
occurred with the blocking antibody Bear-1. CD16 is
known to interact with CR3 on monocytes, enhancing
its ability to bind iC3b [37]. The selective role of CD16
expressed on monocytes may be due to specific inter-
action with CR3 and/or signaling differences between it
and CD32a. This latter could be caused either by differ-
ences in the ITAM motifs located on the FcRγ signaling
protein associated with CD16a and that in the cytoplas-
mic domain of CD32a, or by signaling pathways acti-
vated following phosphorylation of the cytoplasmic
domain of CD16 [38].
Our data, primarily obtained using IE opsonised with
rabbit anti-human RBC antibody, were verified using IE
opsonised with human immune serum. Although wedid not explore the human IgG isotypes required,
studies have shown that anti-malaria antibodies pro-
moting phagocytosis are mainly cytophilic IgG1 and
IgG3 [39, 40]. We used two separate laboratory-
derived P. falciparum lines, CS2 and E8B which were
both more efficiently ingested by CD14hiCD16+
monocytes. These parasite lines express PfEMP1 ad-
hesion molecules on the surface of the IE that bind
with different ligand specificities. Thus, CS2 binds
preferentially to chondroitin sulfate A [29] while E8B
binds to both CD36 and ICAM-1 [34]. Our observa-
tions, therefore, rule out involvement of these receptors
in the increased ability of CD14hiCD16+ monocytes in
phagocytosis.
Imaging flow cytometry verified that under the condi-
tions of our experiments ingestion of IE and not surface
binding were measured. This is important since we
observed that fragments of bound RBC may remain at-
tached to monocytes following hypotonic lysis of the
uningested RBC which can lead to unacceptably high
backgrounds when membrane stains are used to label
target cells. We found that labelling of the parasite DNA
within IE using EtBr was the best approach to use for
measurement of IE phagocytosis, but it has the disad-
vantage that analysis must be performed within 30–60
minutes to avoid loss of the EtBr stain. This lessens the
utility of the whole blood assay used here in clinical
settings.
Our data have uncovered an important role of CD16
expressed on monocytes in responses to IE. Monocytes
express the transmembrane receptor CD16a in contrast
to neutrophils, which express the GPI-linked receptor
CD16b. Although CD16a and CD16b have nearly identi-
cal extracellular domains, they are encoded by separate
genes [41]. Polymorphisms of CD32a and CD16b are as-
sociated with malaria severity [42–45] that may reflect
the ability of splenic macrophages and neutrophils, re-
spectively, to clear opsonised parasites or, in the case of
associations with severe anemia, to ingest uninfected
RBC. Several polymorphisms in CD16a affect either af-
finity for cytophilic IgG subclasses [46] or monocyte
Zhou et al. BMC Medicine  (2015) 13:154 Page 12 of 14expression [47]; however, to our knowledge no studies
have attempted to associate these or other CD16a poly-
morphisms with malaria severity or vaccine responses.
Given the absolute requirement of IE phagocytosis for
CD16 expressed on monocytes revealed herein, such
studies are indicated.
The ability of monocytes to phagocytose IE in whole
blood is decreased relative to that of PBMC prepara-
tions, highlighting the caution that must be employed
when interpreting results using PBMC or purified
monocytes in phagocytosis assays. This may reflect the
presence of inhibitory factors in serum or the large num-
ber of uninfected RBC in whole blood. Uninfected red
blood cells inhibited ingestion of IgG-opsonised tropho-
zoite stage IE consistent with observations of others
using unopsonised schizont-stage IE [35]. We found
similar inhibition of all three monocyte subsets, however,
suggesting that this is unlikely to underlie their differing
phagocytic ability. Interestingly, human RBC membranes
contain an inhibitory factor (phagocytosis-inhibitory fac-
tor, PIF) which appears to affect CR3 conformation and
inhibits ingestion of both C3bi and IgG opsonised latex
beads [48]. We also provide evidence that phagocytosis
by classical and intermediate monocytes in whole blood
is lower than that by these cells in PBMC because of an
inhibitory effect of soluble plasma components. It is pos-
sible that binding of IgG present in serum to Fcγ recep-
tors may contribute to this, since removal of IgG using
protein G sepharose beads reduced inhibition by added
plasma (Additional file 4: Figure S4).
Elevated numbers of CD14hi monocytes which co-
express the chemokine receptors CCR2 and CX3CR1
have been associated with lower parasitemia and in-
creased ADCI activity in P. falciparum-infected individ-
uals with uncomplicated malaria [49]. These cells may
define a specific intermediate monocyte population with
an important protective role against blood stages of the
parasite. It would be of interest to directly compare
ADCI activity of different monocyte subsets and the
phenotype of monocytes with high phagocytic and high
ADCI activity to determine if the same populations are
involved. A selective role for CD14hiCD16+ monocytes
in the response to P. vivax-infected reticulocytes has re-
cently been published [49]. This report differs from our
study in that increased phagocytosis by CD14hiCD16+
monocytes was observed using PBMC preparations incu-
bated for long times (four hours) with purified, infected
reticulocytes. In our hands, discrete monocyte subsets
cannot be identified after four hours incubation of whole
blood with phagocytic targets since CD16 expression on
CD16+ monocytes is decreased. A second difference be-
tween the two studies is that Antonelli et al. [50] used
PBMC prepared from patients with active P.vivax infec-
tion which were shown to be in an activated state,whereas we have studied responses of individuals with
no history of malaria infection and who therefore repre-
sent individuals at risk of primary infection. The differ-
ences between the two studies may also be due to
the different phagocytic targets (P. falciparum-infected
erythrocytes versus P. vivax-infected reticulocytes) used
in the two studies. Nevertheless, both studies point to an
important role for CD14hiCD16+ monocytes in the con-
trol and response to blood-stage malaria infection.
In summary, our data show a special role for
CD14hiCD16+ monocytes in the phagocytosis of
trophozoite-stage P. falciparum IE. The use of whole
blood assays to measure phagocytosis in place of purified
PBMC or monocytes reveals that efficient phagocytosis
requires both IgG opsonisation and complement compo-
nents in situ. Evaluation of vaccine candidates is increas-
ingly employing functional assays such as phagocytosis
assays to determine correlates of immunity. Ideally such
assays should use fresh whole blood, although this may
not be feasible in some field settings. Our data suggest
that care must be taken in interpreting the results of as-
says using purified cells and that the ability of antibodies
to fix complement are likely to be as relevant as opsonic
activity.Conclusions
In the setting of whole blood, human CD14hiCD16+
monocytes are the most efficient subset at ingesting
antibody-opsonised IE. This is not observed in assays
using isolated PBMC where classical and intermediate
monocytes show similar phagocytosis of antibody-
opsonised IE. In whole blood, phagocytosis of IgG-
opsonised IE requires Fcγ receptor IIIa but not other
Fcγ receptors. However Fcγ receptor IIIa is not able to
mediate phagocytosis of IgG-opsonised IE on its own
but requires complement opsonisation of IE. Assays
measuring IE phagocytosis using PBMC or purified
monocyte preparations therefore do not detect critical
elements of antibody-mediated phagocytosis. We con-
clude that assays which measure the ability of vaccines
to elicit a protective antibody response to P. falciparum
should consider their ability to promote phagocytosis
and fix complement.Additional files
Additional file 1: Phagocytosis of E.coli by monocyte subsets
assayed in whole blood. Whole blood from a single donor (100 μL) was
incubated with 2 x 108 pHrodo® Red-labelled Escherichia coli BioParticle
conjugates (Life Technologies) for 10 minutes at either 4 °C or 37 °C as
indicated, then the cells were stained with CD14-APC and CD16-FITC,
and uptake of E.coli determined by flow cytometry. The percentage of
classical (C; black bars), intermediate (IM; white bars) and non-classical
(NC; grey bars) monocytes that had ingested E.coli are plotted.
Zhou et al. BMC Medicine  (2015) 13:154 Page 13 of 14Additional file 2: Effect of red blood cells and autologous plasma
on phagocytosis of antibody-opsonised IE by individual monocyte
subsets. (A) PBMC were mixed with O- erythrocytes at the indicated cell
ratios then phagocytosis of CS2-IE opsonised with rabbit anti human RBC
antibody was measured as described in Methods. Percent phagocytosis
of IE by each subset is expressed relative to the degree of phagocytosis
by the same subset in PBMC alone (zero RBC). Intermediate monocytes (IM),
open circles; classical monocytes (C), closed circles; non-classical monocytes
(NC), open squares. Data represent mean (sem) of four independent
experiments. (B) PBMC washed in PBS containing 2 % FBS were resuspended
in PBS containing the indicated final concentrations of autologous plasma,
then phagocytosis of CS2-IE opsonised with rabbit anti human RBC antibody
was measured as described in Methods. Percent phagocytosis of each subset
defined as in (A) is expressed relative to phagocytosis by the same subset in
PBMC alone (zero added autologous plasma). Data represent mean (sem) of
four independent experiments.
Additional file 3: AMNIS Image Stream flow cytometric analysis
of phagocytosis of antibody-opsonised IE by monocytes.
Phagocytosis of PKH26-labelled CS2-IE opsonised with rabbit anti
human RBC antibody by monocyte subsets was analysed by imaging
flow cytometry as described in Methods. (A) Gating strategy used to
exclude events that were not in focus (left panel) or cell doublets
(middle panel) and to identify the individual monocyte subsets (right panel).
(B) Representative images of a classical monocyte (C: CD14hiCD16-; top panel),
an intermediate monocyte (IM: CD14hiCD16+; middle panel) and a
non-classical monocyte (NC: CD14loCD16+; lower panel) from the respective
gates defined in (A) above. (C) Representative images of three monocytes
within the intermediate monocyte gate containing ingested parasites
(indicated on the bright field image by arrows) and showing co-localisation
of CD16 and PKH26. Due to the differences in brightness of the fluorophores
used, it was difficult to depict CD14 on the co-localisation panels; however,
all monocytes within the intermediate monocyte gate stained positive for
both CD14 and CD16 as shown in the representative cell illustrated in the IM
panels in (B). The numbers within the bright field images in Fig. 2c refer to
the event number assigned by the IDEAS software.
Additional file 4: Inhibition of iRBC phagocytosis following addition
of heat inactivated serum and Ig-depleted heat-inactivated serum.
A total of 0.5 mL of human serum was heat inactivated for 30 minutes at
56 °C. One half of the serum was depleted of immunoglobulins by
incubation with 125 μL Protein G sepharose (Pharmacia) for 20 minutes
at room temperature with constant mixing, then the Protein G was
removed by centrifugation. PBMC (0.5 x 106) were incubated with 1 x 107
IE (CS2-infected RBC opsonised with rabbit anti-human IgG) in the
presence of either 0 or 50 % treated and untreated serum. Phagocytosis
by classical (C), intermediate (IM and non-classical (NC) monocyte subsets
was measured as described in Methods. The percent phagocytosis of each
subset is expressed as a percentage of that of the same subset measured
in the absence of added serum (0). Black bars: heat inactivated serum.
Open bars; Ig-depleted, heat-inactivated serum.
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